This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wiench, M. Articles by Jarzab, B. Search for Related Content PubMed PubMed Citation Articles by Wiench, M. Articles by Jarzab, B. Social Bookmarking                            What's this?

Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients

From the Departments of Nuclear Medicine and Endocrine Oncology, Tumor Biology, Clinic of Oncological Surgery, and the Department of Pathology, Center of Oncology, Maria Sklodowska-Curie Memorial Institute, Gliwice; and the Department of Endocrinology, Medical Center of Postgraduate Education, Warsaw, Poland.

Address reprint requests to Barbara Jarzab, MD, Department of Nuclear Medicine and Endocrine Oncology, Center of Oncology, Maria Sklodowska-Curie Memorial Institute, Wybrzeze AK 15, 44-101 Gliwice, Poland; email: bjarzab{at}io.gliwice.pl

PURPOSE: The study was undertaken to evaluate the frequency of inherited medullary thyroid carcinoma (MTC) among patients with apparent sporadic disease. A stepwise algorithm was used depending on clinical indices and the age of patient at MTC diagnosis.

PATIENTS AND METHODS: One hundred sixteen patients with MTC verified by postoperative pathologic examination were subjected to genetic analysis of RET exons 10, 11, 13, 14, and 16 by means of polymerase chain reaction, restriction endonuclease digestion, and DNA sequencing.

RESULTS: Among 116 apparent sporadic MTC patients, we identified eleven (9.5%) RET germline mutation carriers. Seven of these (6.0%) were found by routine analysis (exons 10 and 11). The frequency of inherited disease among patients younger than 45 years at diagnosis was 10.2% by analysis of typical mutations in exons 10 and 11. Extended genetic analysis (sequencing of exons 11, 13, 14, and 16) yielded 6.1% additional diagnoses, giving a risk of 16.3% in this age group. One previously unreported mutation in exon 11 affected codon 649 (TCG>TTG, Ser>Leu). In the true sporadic MTC patients younger than 30 years at diagnosis, frequencies of 36% and 4.5% in polymorphic variants L769L and S836S, respectively, were observed. The frequency for L769L was higher than in older patients (P < .05).

CONCLUSION: The frequency of inherited disease among apparent sporadic medullary thyroid carcinoma patients is close to 10% in the Polish population of MTC patients. The extended analysis of all known RET proto-oncogene mutation sites is obligatory in patients younger than 45 years at diagnosis, but we also see the need to analyze the impact of rarer mutations in older patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Colombo-Benkmann, Z. Li, B. Riemann, K. Hengst, H. Herbst, R. Keuser, U. Gross, S. Rondot, F. Raue, N. Senninger, et al. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 811 - 816. [Abstract] [Full Text] [PDF]

				R. Elisei, C. Romei, B. Cosci, L. Agate, V. Bottici, E. Molinaro, M. Sculli, P. Miccoli, F. Basolo, L. Grasso, et al. RET Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4725 - 4729. [Abstract] [Full Text] [PDF]

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				M Montani, A M Schmitt, S Schmid, T Locher, P Saremaslani, P U Heitz, P Komminoth, and A Perren No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma Endocr. Relat. Cancer, December 1, 2005; 12(4): 1011 - 1016. [Abstract] [Full Text] [PDF]

				S. M. Baumgartner-Parzer, R. Lang, L. Wagner, G. Heinze, B. Niederle, K. Kaserer, W. Waldhausl, and H. Vierhapper Polymorphisms in Exon 13 and Intron 14 of the RET Protooncogene: Genetic Modifiers of Medullary Thyroid Carcinoma? J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6232 - 6236. [Abstract] [Full Text] [PDF]

				A. M. Alvares Da Silva, R. M. B. Maciel, M. R. Dias Da Silva, S. R. C. Toledo, M. B. De Carvalho, and J. M. Cerutti A Novel Germ-Line Point Mutation in RET Exon 8 (Gly533Cys) in a Large Kindred with Familial Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5438 - 5443. [Abstract] [Full Text] [PDF]

				H. Dannenberg, W. N. M. Dinjens, M. Abbou, H. van Urk, B. K. H. Pauw, D. Mouwen, W. J. Mooi, and R. R. de Krijger Frequent Germ-Line Succinate Dehydrogenase Subunit D Gene Mutations in Patients with Apparently Sporadic Parasympathetic Paraganglioma Clin. Cancer Res., July 1, 2002; 8(7): 2061 - 2066. [Abstract] [Full Text] [PDF]

				L. Kasprzak, S. Nolet, L. Gaboury, C. Pavia, C. Villabona, F. Rivera-Fillat, J. Oriola, and W. D Foulkes Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET J. Med. Genet., November 1, 2001; 38(11): 784 - 787. [Full Text] [PDF]